Panel Discussion: Revitalizing the ALS Investment Landscape: Opportunities, Challenges, & the Path Forward
9:30 am - Thursday 4th June 2026
- What are the current barriers to investment in ALS therapeutics, and how can stakeholders address perceived scientific or clinical risks?
- Which emerging modalities or targets in ALS are attracting the most investor interest, and where do pharma companies see the greatest potential for collaboration?
- How can early-stage data, biomarkers, or patient-focused endpoints help de-risk ALS programs for investors and facilitate pharma partnerships?
- What lessons can be learned from past ALS investment successes and failures to guide more sustainable funding strategies?
- How can collaboration between VCs, corporate pharma, and patient advocacy groups accelerate both funding and development of ALS therapies?
Speakers:
Vice President, Head of Search & Evaluation, Business Development - Innovative Medicine
Teva Pharmaceuticals
